Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis

Part of paid clinical trials in Providence, Rhode Island.

Sponsor
Rhode Island Hospital
Study ID
NCT05990881
Phase
PHASE3
Status
Recruiting

Conditions

  • Carpometacarpal Sprain
  • Clostridium; Botulinum
  • Thumb Sprain

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Botulinum toxin — DRUG
    Patients in this group will receive an injection of Botulinum toxin.
  • Standard-of-care corticosteroid injections — DRUG
    Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.

Study Details

The purpose of this clinical trial is to gather information on the safety and effectiveness of botulinum toxin injection (or Botox) in the treatment of thumb joint pain/arthritis. People with thumb joint pain or arthritis usually receive steroid injections to help with the pain. However, this medicine does not always work well and also carries known important side effects. There is currently no alternative to this injection medicine. This clinical trial seeks to investigate botulinum toxin as a possible alternative to steroid injection. The difference between Botox and steroid injections is that they are different medicines and work in different ways. Botox, as it is being used in this study, is not FDA-approved. It is therefore considered an investigational medicine.

Key Dates

Start date
Aug 27, 2023
Status verified
Nov 2024
Primary completion
Dec 31, 2025
Completion
Jul 31, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Control
    Patients in this group will receive standard-of-care corticosteroid injections.
  • Experimental: Botulinum Toxin
    Patients in this group will receive a Botulinum Toxin injection.

Primary Outcome Measure

Thumb Pain [ Time Frame: Post-injection VAS scores will then be taken at each subsequent follow-up visit: 2-weeks, 1-month, 6-months, and 1-year (primary study endpoint). ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
235 Plain StreetProvidenceRhode Island02905
Reena A Bhatt, MD
(401) 444-2701
Sarah A Uriarte, BS
323-528-4514

Find similar trials in Providence, RI